Study of PF-07265807 in Participants With Metastatic Solid Tumors.

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.

Conditions

Neoplasm Metastasis

Interventions

DRUG: PF-07265807
DRUG: Sasanlimab
DRUG: Axitinib

Sponsor

Pfizer